AMSTERDAM, Sept 24 (Reuters) – The second-largest
shareholder in Dutch biotechnology firm Crucell
, which has criticised Johnson & Johnson’s
$2.3 billion offer for the company as meagre, has
increased its stake since the bid.
According to a Sept. 22 filing with the Dutch market
regulator AFM, Van Herk Group holds 10.02 percent of Crucell
shares, up from 9.6 percent in a filing of December 2009.